[Combined preoperative therapy for oral cancer with nedaplatin and radiation].
We performed preoperative combined therapy using nedaplatin (CDGP) and radiation in 12 patients with squamous cell carcinoma originating from the oral cavity and maxillary sinus, and examined for any adverse events that may have occurred during this therapeutic regimen. Regarding the irradiation, external irradiation utilizing a 6 MV linac (linear accelerator) at a dose of 2.0 Gy/day was performed 5 times a week, with the target total radiation dose set at 40 Gy. In addition, CDGP was intravenously administered 30 minutes before irradiation at a dose of 5 mg/m2/day. Mucositis was observed in all 12 subjects, however, the severity was observed to be grade 1-2 with no major differences in comparison to the patients given standard radiation monotherapy. Two subjects developed grade 3 leucopenia and were thus given granulocyte colony stimulating factor (G-CSF). In addition, grade 2 and grade 3 thrombocytopenia were both observed in one subject each. The subject with grade 3 thrombocytopenia required a platelet transfusion during surgery. No marked changes in serum creatinine levels were noted. These findings are therefore considered to provide evidence supporting the safety of this combination therapy.
Adachi
Masatoshi
M
Clinical Center for Oral and Maxillofacial Oncology, Nippon Dental University Hospital.
Shibata
Akihiko
A
Hayashi
Munehiro
M
Satoh
Daigo
D
Miyasaka
Takahiro
T
Yanai
Chie
C
Kawatsu
Noritoshi
N
Yagishita
Hideo
H
Ogino
Yasuhito
Y
Yamashita
Noriaki
N
Suzuki
Munekazu
M
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D011300:Preoperative Care; D011882:Radiotherapy, High-Energy
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C053989:nedaplatin